VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs

VOLITIONRX LTD

Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.
Cash and equivalents $10.8M as of Sep 30, 2023, roughly flat vs year-end 2022.
Post-quarter: Walloon funding approved for ~$6M; expects $13M milestone payments from Heska.
FDA agreed to traditional 510(k) pathway for Nu.Q NETs test following Q-Sub process.
Launched Nu.Q Vet Test in UK/Ireland via NationWide Laboratories and Veterinary Pathology Group.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

VOLITIONRX LTD reported the third quarter ended September 30, 2023 results: revenue $531,000.

Period: the third quarter ended September 30, 2023
Revenue: $531,000
Result: reported results

Exact text from the filing

over the prior year period, reflecting sales of the reference kits through our global, regional and local supply agreements. Additionally, total year-to-date revenue was $531,000, a 185% increase compared to the comparable period of 2022. We believe that these results demonstrate steady growth, but not yet the “ramp” in revenues that we anticipate. We

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-23-008448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.